Poly-cyclodextrin and poly-paclitaxel nano-assembly for anticancer therapy

Nature Communications

Volumn 5, Issue , 2014, Pages

  Namgung, Ran ^a,b   Mi Lee, Yeong ^a,b   Kim, Jihoon ^a,b   Jang, Yuna ^a,b   Lee, Byung Heon ^c   Kim, In San ^c,d   Sokkar, Pandian ^a,b   Rhee, Young Min ^a,b   Hoffman, Allan S ^e,f   Kim, Won Jong ^a,b  

^a Institute for Basic Science   (South Korea)

^b Pohang University of Science and Technology (POSTECH)   (South Korea)

^c Kyungpook National University School of Medicine   (South Korea)

^d Korea Institute of Science and Technology   (South Korea)

^e UNIVERSITY OF WASHINGTON   (United States)

^f Kyungpook National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLODEXTRIN; PACLITAXEL; POLYCYCLODEXTRIN; POLYMER; POLYPACLITAXEL; UNCLASSIFIED DRUG; CELLULOSE; CYCLODEXTRIN POLYMER; DRUG CARRIER; NANOPARTICLE;

CANCER; CELL ORGANELLE; DISEASE CONTROL; DRUG; POLYMER; TUMOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; FEMALE; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; HELA CELL LINE; MCF 7 CELL LINE; NEOPLASMS; NUDE MOUSE; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELLULOSE; CYCLODEXTRINS; DRUG CARRIERS; FEMALE; HELA CELLS; HUMANS; MCF-7 CELLS; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR DYNAMICS SIMULATION; NANOPARTICLES; NEOPLASM TRANSPLANTATION; NEOPLASMS; PACLITAXEL; POLYMERS; TRANSPLANTATION, HETEROLOGOUS;

EID: 84900028669     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms4702     Document Type: Article

References (45)

1. Maeda, H., Ueda, M., Morinaga, T. & Matsumoto, T. Conjugation of poly(styrene-co-maleic acid) derivatives to the antitumor protein neocarzinostatin: pronounced improvements in pharmacological properties. J. Med. Chem. 28, 455-461 (1985).
2. Maeda, H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv. Drug Deliv. Rev. 46, 169-185 (2001).
3. Osada, K. et al. Bioactive polymeric metallosomes self-assembled through block copolymer-metal complexation. J. Am. Chem. Soc. 134, 13172-13175 (2012).
4. Bae, Y. et al. Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy. Bioconjug. Chem. 16, 122-130 (2005).
5. Haag, R. & Kratz, F. Polymer therapeutics: concepts and applications. Angew. Chem. Int. Ed. 45, 1198-1215 (2006).
6. Griset, A. P. et al. Expansile nanoparticles: synthesis, characterization, and in vivo efficacy of an acid-responsive polymeric drug delivery system. J. Am. Chem. Soc. 131, 2469-2471 (2009).
7. Thierry, B. et al. Delivery platform for hydrophobic drugs: prodrug approach combined with self-assembled multilayers. J. Am. Chem. Soc. 127, 1626-1627 (2005).
8. Lee, E. et al. Conjugated chitosan as a novel platform for oral delivery of paclitaxel. J. Med. Chem. 51, 6442-6449 (2008).
9. Wang, Y., Xin, D., Liu, K., Zhu, M. & Xiang, J. Heparin-paclitaxel conjugates as drug delivery system: synthesis, self-assembly property, drug release, and antitumor activity. Bioconjug. Chem. 20, 2214-2221 (2009).
10. Cavallaro, G., Licciardi, M., Caliceti, P., Salmaso, S. & Giammona, G. Synthesis, physico-chemical and biological characterization of a paclitaxel macromolecular prodrug. Eur. J. Pharm. Biopharm. 58, 151-159 (2004).
11. Xie, Z. et al. A novel polymer-paclitaxel conjugate based on amphiphilic triblock copolymer. J. Control. Release 117, 210-216 (2007).
12. Bae, Y., Fukushima, S., Harada, A. & Kataoka, K. Design of environmentsensitive supramolecular assemblies for intracellular drug delivery: polymeric micelles that are responsive to intracellular pH change. Angew. Chem. Int. Ed. 42, 4640-4643 (2003).
13. Davis, M. E. & Brewster, M. E. Cyclodextrin-based pharmaceutics: past, present and future. Nat. Rev. Drug Discov. 3, 1023-1035 (2004).
14. Brewster, M. E. & Loftsson, T. Cyclodextrins as pharmaceutical solubilizers. Adv. Drug Deliv. Rev. 59, 645-666 (2007).
15. Loftsson, T. & Brewster, M. E. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J. Pharm. Sci. 85, 1017-1025 (1996).
16. Layre, A. M., Wintgens, V., Gosselet, N. M., Dalmas, F. & Amiel, C. Tuning the interactions in cyclodextrin polymer nanoassemblies. Eur. Polym. J. 45, 3016-3026 (2009).
17. Nielsen, A. L., Steffensen, K. & Larsen, K. L. Self-assembling microparticles with controllable disruption properties based on cyclodextrin interactions. Colloids Surf. B 73, 267-275 (2009).
18. Skwarczynski, M., Hayashi, Y. & Kiso, Y. Paclitaxel prodrugs: toward smarter delivery of anticancer agents. J. Med. Chem. 49, 7253-7269 (2006).
19. Jordan, M. A. & Wilson, L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 4, 253-265 (2004).
20. Gelderblom, H., Verweij, J., Nooter, K. & Sparreboom, A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer 37, 1590-1598 (2001).
21. Alcaro, S. et al. Preparation, characterization, molecular modelling and in vitro activity of paclitaxel-cyclodextrin complexes. Bioorg. Med. Chem. Lett. 12, 1637-1641 (2002).
22. Liu, Y. et al. Inclusion complexation and solubilization of paclitaxel by bridged bis(b-cyclodextrin)s containing a tetraethylenepentaamino spacer. J. Med. Chem. 46, 4634-4637 (2003).
23. Hamada, H., Ishihara, K., Masuoka, N., Mikuni, K. & Nakajima, N. Enhancement of water-solubility and bioactivity of paclitaxel using modified cyclodextrins. J. Biosci. Bioeng. 102, 369-371 (2006).
24. Thiele, C., Auerbach, D., Jung, G. & Wenz, G. Inclusion of chemotherapeutic agents in substituted b-cyclodextrin derivatives. J. Incl. Phenom. Macrocycl. Chem. 69, 303-307 (2011).
25. Jiao, P. et al. Leading neuroblastoma cells to die by multiple premeditated attacks from a multifunctionalized nanoconstruct. J. Am. Chem. Soc. 113, 13918-13921 (2011).
26. Benito, J. M. et al. Optimizing saccharide-directed molecular delivery to biological receptors: design, synthesis, and biological evaluation of glycodendrimer-cyclodextrin conjugates. J. Am. Chem. Soc. 126, 10355-10363 (2004).
27. Moser, J. G., Rose, I., Wagner, B., Wieneke, T. & Vervoorts, A. Taxol inclusion complexes with a cyclodextrin dimer: possibilities to detoxify chemotherapeutics and to target drugs specifically to tumors J. Incl. Phenom. Macrocycl. Chem. 39, 13-18 (2001).
28. Ruebner, A. et al. Dimeric cyclodextrin carriers with high binding affinity to porphyrinoid photosensitizers. J. Incl. Phenom. Mol. Recognit. Chem. 27, 69-84 (1997).
29. Joseph, J., Dreiss, C. A. & Cosgrove, T. Rupturing polymeric micelles with cyclodextrins. Langmuir. 23, 460-466 (2007).
30. Ferreira, S. A., Coutinho, P. J. G. & Gama, F. M. Self-assembled nanogel made of mannan: synthesis and characterization. Langmuir. 26, 11413-11420 (2010).
31. Lee, H., De Vries, A. H., Marrink, S.-J. & Pastor, R. W. A coarse-grained model for polyethylene oxide and polyethylene glycol: conformation and hydrodynamics. J. Phys. Chem. B 113, 13186-13194 (2009).
32. Charlot, A. & Auzely-Velty, R. Synthesis of novel supramolecular assemblies based on hyaluronic acid derivatives bearing bivalent b-cyclodextrin and adamantane moieties. Macromolecules 40, 1147-1158 (2007).
33. Charlot, A. & Auzely-Velty, R. Novel hyaluronic acid based supramolecular assemblies stabilized by multivalent specific interactions: rheological behavior in aqueous solution. Macromolecules 40, 9555-9563 (2007).
34. Flores, M. L. et al. Paclitaxel sensitivity of breast cancer cells requires efficient mitotic arrest and disruption of Bcl-xL/Bak interaction. Breast Cancer Res. Treat. 133, 917-928 (2012).
35. Leland, P. et al. Human breast carcinoma cell express type II IL-4 receptors and are sensitive to antitumor activity of a chimeric IL-4-pseudomonas exotoxin fusion protein in vitro and in vivo. Mol. Med. 6, 165-178 (2000).
36. Jeon, J. O. et al. Designed nanocage displaying ligand-specific peptide bunches for high affinity and biological activity. ACS Nano 7, 7462-7471 (2013).
37. Yang, F. Y. et al. Treating glioblastoma multiforme with selective high-dose liposomal doxorubicin chemotherapy induced by repeated focused ultrasound. Int. J. Nanomedicine 7, 965-974 (2012).
38. Matsumura, Y. Preclinical and clinical studies of NK012, an SN-38-incorporating polymeric micelles, which is designed based on EPR effect. Adv. Drug Deliv. Rev. 63, 184-192 (2011).
39. Cheng, J., Khin, K. T., Jensen, G. S., Liu, A. & Davis, M. E. Synthesis of linear, b-cyclodextrin-based polymers and their camptothecin conjugates. Bioconjug. Chem. 14, 1007-1017 (2003).
40. Davis, M. E. Design and development of IT-101, a cyclodextrin-containing polymer conjugate of camptothecin. Adv. Drug Deliv. Rev. 61, 1189-1192 (2009).
41. Rong, D. & DSouza, V. T. A convenient method for functionalization of the 2-position of cyclodextrins. Tetrahedron Lett. 31, 4275-4278 (1990).
42. Renard, E., Volet, G. & Amiel, C. Synthesis of a novel linear water-soluble b-cyclodextrin polymer. Polym. Int. 54, 594-599 (2005).
43. Volet, G. & Amiel, C. pH sensitive supramolecular assembling system between a new linear water soluble b-cyclodextrin terpolymer and an amphiphilic poly(ethylene oxide). Eur. Polym. J. 45, 852-862 (2009).
44. Weickenmeier, M. & Wenz, G. Cyclodextrin sidechain polyesters-synthesis and inclusion of adamantan derivatives. Macromol. Rapid Commun. 17, 731-736 (1996).
45. Xiong, Y. et al. A poly(g, L-glutamic acid)-citric acid based nanoconjugate for cisplatin delivery. Biomaterials 33, 7182-7193 (2012).